In the case of prostate cancer, the expression of this protein tends to be associated with tumor differentiation.(10) The radiopharmaceutical labeled with gallium 68, 68Ga-PSMA-11-HBED-CC, or simply 68Ga-PSMA, is a synthetic antigen inhibitor that, when injected into the patient, binds to the cells of the primary prostate cancer and its metastases. This evidence concerns the gene FOLH1 and prostate carcinoma.